[1]曹莉明,张勇学,梁志会,等.载药微球栓塞治疗传统TACE抵抗的原发性肝癌临床疗效[J].介入放射学杂志,2023,32(01):59-62.
　CAO Liming,ZHANG Yongxue,LIANG Zhihui,et al.Drug-eluting beads-trancatheter arterial chemoembolization for the treatment of hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization: observation of its clinical effect[J].journal interventional radiology,2023,32(01):59-62.
点击复制

载药微球栓塞治疗传统TACE抵抗的原发性肝癌临床疗效()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年01
页码:
59-62
栏目:
临床研究
出版日期:
2023-02-13

文章信息/Info

Title:
Drug-eluting beads-trancatheter arterial chemoembolization for the treatment of hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization: observation of its clinical effect
作者:
曹莉明; 　张勇学; 　梁志会; 　李　亮; 　崔进国
Author(s):
CAO Liming;  ZHANG Yongxue;  LIANG Zhihui;  LI Liang;  CUI Jinguo.
Department of Interventional Therapy, No.980 Hospital of PLA Joint Logistics Support Forces （Bethune International Peace Hospital）, Shijiazhuang, Hebei Province 050082, China
关键词:
【关键词】原发性肝癌; TACE抵抗; 肝硬化; 肝动脉化疗栓塞术; 载药微球
文献标志码:
A
摘要:
【摘要】　目的　评价载药微球经导管动脉化疗栓塞（drug-eluting beads-trancatheter arterial chemoembolization，DEB-TACE）治疗对传统导管动脉化疗栓塞（transcatheter arterial chemoembolization，TACE）抵抗的原发性肝癌的安全性及有效性。方法　回顾分析2017年1月至2021年1月解放军联勤保障部队第九八〇医院对传统TACE抵抗的原发性肝癌行DEB-TACE治疗25例患者的临床资料，采用改良实体瘤疗效评价标准（ mRECIST）统计分析临床疗效，比较治疗前后肝功能变化，记录并发症发生情况。结果　25例患者共实施DEB-TACE治疗36例次，栓塞终点为肿瘤染色消失，供血动脉闭塞。根据mRECIST标准，DEB-TACE术后1个月、3个月和6个月患者的客观缓解率（ORR）分别为92%、72%和60%，疾病控制率（DCR）分别为96%、88%和80%。DEB-TACE术后第3天，AST和ALT升高，差异有统计学意义（P＜0.05），术后7 d逐步好转，术后30 d恢复至术前水平，与术前比较差异无统计学意义（P＞0.05）。总胆红素及白蛋白变化不大，治疗前后差异无统计学意义（P＞0.05）。未出现肝衰竭、肝脓肿及骨髓抑制等严重并发症。结论　DEB-TACE治疗对传统TACE抵抗的中期原发性肝癌安全、有效。

参考文献/References:

［1］　Llovet JM, Kelley RK, Villanueva A. Hepatocellular carcinoma［J］. Nat Rev Dis Primers, 2021, 7:6.
［2］　魏矿荣，彭侠彪，梁智恒，等. 全球肝癌流行概况［J］. 中国肿瘤，2015，24：621-630．
［3］　European Association for the Study of the Liver. Corrigendum to "EASL Clinical Practice Guidelines: management of hepatocellular carcinoma" ［J Hepatol 69 （2018） 182-236］［J］. J Hepatol, 2019,70:817.
［4］　吴孟超，汤钊猷，刘允怡，等. 原发性肝癌诊疗规范（2019 年版）［J］. 中华消化外科杂志，2020，19：1-2．
［5］ Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 （4th JSH‐HCC guidelines） 2019 update［J］. Hepatol Res, 2019, 49: 1109-1113.
［6］ Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies［J］. Cardiovasc Intervent Radiol, 2006, 30: 6-25.
［7］　余晨曦，滕皋军. 经导管动脉化疗栓塞术抵抗研究进展［J］. 介入放射学杂志，2017，26：1063-1067．
［8］ Kajihara J, Tomimaru Y, Eguchi H, et al. The clinical impact of transcatheter arterial chemoembolization （TACE）-induced c-Met upregulation on TACE refractoriness in hepatocellular carcinoma［J］. Dig Dis Sci, 2016, 61: 1572-1581.
［9］ Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update［J］. Oncology, 2014, 87（Suppl 1）: 22-31.
［10］ Ikeda M, Mitsunaga S, Shimizu S, et al. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization［J］. J Gastroenterol, 2014, 49: 932-940.
［11］ Chen P, Yuan P, Chen B, et al. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis［J］. Clin Res Hepatol Gastroenterol, 2017, 41:75-85.
［12］ Sun J, Zhou G, Xie X, et al. Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres? in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres? transarterial chemoembolization in liver cancer （CTILC） study［J］. Oncol Res, 2020, 28: 75-94.
［13］ Poyanli A, Rozanes I, Acunas B, et al. Palliative treatment of hepatocellular carcinoma by chemoembolization［J］. Acta radiol, 2001, 42: 602-607.
［14］张　申，张　磊，仲斌演，等．“TACE抵抗/失败”——需要全面认识［J］. 介入放射学杂志，2020，29：743-747．
［15］王文辉，李宝华，李　雷，等. 载药微球治疗中期原发性肝癌25例［J］. 介入放射学杂志，2021，30：270-274．
［16］ Vesselle G, Quirier-Leleu C, Velasco S, et al. Predictive factors for complete response of chemoembolization with drug-eluting beads （DEB-TACE） for hepatocellular carcinoma［J］. Eur Radiol, 2016, 26: 1640-1648.
［17］ Zhang X, Lin X, Qiu H, et al. An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres? microspheres in treating Chinese hepatocellular carcinoma patients［J］. J Clin Lab Anal, 2019, 33: e22975.

相似文献/References:

[1]徐中琪,刘晟,许贇,等.完全性胸腹腔内脏反位合并原发性肝癌行经皮微波消融治疗4例[J].介入放射学杂志,2016,(06):546.
　XU Zhong-qi,LIU Sheng,XU Yun,et al.Percutaneous microwave ablation for primary hepatocellular carcinoma in patients with thoracic and abdominal situs inversus totalis: report of 4 cases [J].journal interventional radiology,2016,(01):546.
[2]仲斌演,王万胜,张 申,等.TACE抵抗的重新认知：一项中国医师协会介入医师分会发起的调查研究[J].介入放射学杂志,2023,32(07):642.
　ZHONG Binyan,WANG Wansheng,ZHANG Shen,et al.Re-understanding of TACE failure/refractoriness： a survey initiated by the Chinese College of Interventionalists[J].journal interventional radiology,2023,32(01):642.
[3]徐永康,付舒敏,李　丹,等.肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展[J].介入放射学杂志,2023,32(01):94.
　XU Yongkang,FU Shumin,LI Dan,et al.Research progress in hepatic arterial infusion chemotherapy combined with systemic therapy for the treatment of primary hepatocellular carcinoma[J].journal interventional radiology,2023,32(01):94.
[4]沈晓娣,叶盼,边雪梅,等.基于抑木扶土理论的气交灸联合揿针干预经导管肝动脉化疗栓塞术后疼痛、恶心呕吐的临床研究[J].介入放射学杂志,2024,33(09):1014.
　SHEN Xiaodi,YE Pan,BIAN Xuemei,et al.The“suppressing wood-supporting earth” theory-based air moxibustion combined with pushpin-like needle acupuncture in the treatment of pain，nausea and vomiting after TACE：a clinical study[J].journal interventional radiology,2024,33(01):1014.

备注/Memo

备注/Memo:
（收稿日期：2021-11-05）
（本文编辑：新　宇）
更新日期/Last Update: 2023-02-13